InsidersTradesSigma
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
6
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-27.8%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Rachman Ilya M, Chairman & CEO. Director active across 1 company, notably Immix Biopharma, Inc.. In total, 7 disclosures have been recorded. Breakdown: 6 buys · 0 sell. Total volume traded: €39k. History available since 20 December 2021. The latest transaction was filed on 18 June 2025 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations7 total
2,178 shares@ US$2.295Common StockSEC:0001641172-25-015756:0
Ideal exit: 15 Mar 2026 (T+270)
2,600 shares@ US$2.1311.1% of flowCommon StockSEC:0001493152-24-023287:0
Ideal exit: 4 Mar 2025 (T+270)
3,300 shares@ US$1.809112.0% of flowCommon StockSEC:0001493152-24-022653:0
Ideal exit: 1 Mar 2025 (T+270)
218,359 sharesCommon StockSEC:0001493152-24-020778:0
4,300 shares@ US$2.246519.5% of flowCommon StockSEC:0001493152-24-019366:0
Ideal exit: 8 Feb 2025 (T+270)
4,050 shares@ US$1.0198.7% of flowCommon StockSEC:0001493152-22-032557:0
Ideal exit: 11 Aug 2023 (T+270)
2,500 shares@ US$5.000.0021% mcap50.0% of flowCommon StockSEC:0001493152-21-032038:0
Ideal exit: 16 Sept 2022 (T+270)
7 of 7 declarations
About Rachman Ilya M
Ilya M. Rachman is the CEO and Chairman of Immix Biopharma, Inc., a biopharmaceutical company. He oversees the strategic direction of the company and manages its operations. His expertise in the biopharmaceutical sector allows him to lead initiatives aimed at developing new treatments and improving patient outcomes.
